Standard (N=20) | HPSD (N=100) | P | |
Age (mean ± SD, min-max) | 66.4 ± 10 (45 - 80) | 66,4 ± 10 (35 - 80) |
0,99
|
Sex male female | 7/20 (35%) 13/20 (65%) | 60/100 (60%) 40/100 (40%) |
0,04
|
LV-EF (mean ± SD, min-max) | 59.5 ± 5.5 (45 - 65) | 54.2 ± 13.3 (10 - 65) |
0,08
|
AF type paroxysmal persistent | 9/20 (45%) 11/20 (55%) | 49/100 (49%) 51/100 (51) |
0.74
|
EHRA stage I: IIa: IIb: III: IV: | 0/20 (0%) 1/20 (5%) 5/20 (25%) 11/20 (55%) 3/20 (15%) | 1/100 (1%) 8/100 (8%) 26/100 (26%) 56/100 (56%) 9/100 (9%) |
0.94
|
CHA2DS2-VASc (mean ± SD, min-max)
|
3.2 ± 1.5 (1 - 6) | 2.8 ± 1.5 (0 - 7) |
0,34
|
Medications Betablockers Flecainide Amiodarone | 19/20 (95%) 1/20 (5%) 5/20 (25%) | 89/100 (89%) 6/100 (6%) 24/100 (24%) | 0.41 0.86 0.92 |